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Cancer  is  a complex  disease  resulting  from  the uncontrolled  proliferation  of cell  signaling  events.  Protein
kinases  have  been  identiﬁed  as  central  molecules  that  participate  overwhelmingly  in oncogenic  events,
thus  becoming  key  targets  for  anticancer  drugs.  A  majority  of  studies  converged  on  the  idea that  ligand-
binding  pockets  of kinases  retain  clues  to  the  inhibiting  abilities  and cross-reacting  tendencies  of inhibitor
drugs.  Even  though  these  ideas  are  critical  for drug  discovery,  validating  them  using  experiments  is  not
only  difﬁcult,  but also  in some  cases  infeasible.  To  overcome  these  limitations  and  to  test  these  ideas  at the
molecular  level,  we  present  here  the  results  of receptor-focused  in-silico  docking  of  nine  marketed  drugs
to 19  different  wild-type  and  mutated  kinases  chosen  from  a wide  range  of  families.  This  investigation
highlights  the need  for using  relevant  models  to explain  the correct  inhibition  trends  and  the  results  are
used  to make  predictions  that might  be  able  to  inﬂuence  future  experiments.  Our  simulation  studies  are
able to correctly  predict  the  primary  targets  for each  drug  studied  in  majority  of  cases  and our results
agree  with  the  existing  ﬁndings.  Our  study  shows  that  the conformations  a given  receptor  acquires  during
kinase  activation,  and  their micro-environment,  deﬁnes  the  ligand  partners.  Type  II drugs  display  high
compatibility  and  selectivity  for DFG-out  kinase  conformations.  On  the other  hand  Type  I drugs  are  less
selective  and  show  binding  preferences  for both  the  open  and  closed  forms  of  selected  kinases.  Using  this
receptor-focused  approach,  it is  possible  to capture  the  observed  fold  change  in  binding  afﬁnities  between
the  wild-type  and  disease-centric  mutations  in ABL kinase  for  Imatinib  and  the second-generation  ABL
drugs.  The  effects  of  mutation  are  also investigated  for two  other  systems,  EGFR  and  B-Raf.  Finally,  by
including  pathway  information  in the design  it is possible  to  model  kinase  inhibitors  with  potentially
fewer  side-effects.
© 2015  The  Authors.  Published  by  Elsevier  Inc.  This  is an  open  access  article  under  the  CC  BY-NC-ND. Introduction
Cancer continues to be a major cause of death among the human
iseases. As per the latest statistics [1], new US cancer cases and
eaths continues to be a major health concern, and for 2014 they
re estimated to be around 1,665,540 and 585,720 respectively.
ence, there is an urgent need for novel cancer drugs with fewer
ide effects. Protein kinases are enzymes that help carry out the
ransfer of a phosphate group (phosphorylation) from ATP to sub-
trate proteins [2–4] and play an important role in cancer and signal
ransduction pathways. So far, approximately 518 kinase genes
5,6] have been identiﬁed in the human genome, which amounts to
bout 1.7% of the total 20-25 K genes. Protein phosphorylation is, in
ost cases, initiated by extracellular signals and acts like a switch
∗ Corresponding author. Tel.: +1 301 846 1991; fax: +1 301 846 5762.
E-mail address: ravichandrans@mail.nih.gov (S. Ravichandran).
ttp://dx.doi.org/10.1016/j.jmgm.2014.12.007
093-3263/© 2015 The Authors. Published by Elsevier Inc. This is an open access article unlicense  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
to control a substrate’s binding afﬁnity, receptor’s enzymatic activ-
ity, and the cellular location of their products. These actions can, in
turn, inﬂuence down-stream gene/protein functions. Kinases also
act as effectors and participate in a wide-range of important cellular
functions ranging from cell cycle modulation, DNA repair, immu-
nity, growth, and apoptosis. Since kinase activity inﬂuences many
cellular functions, its regulatory role is usually kept under tight con-
trol. Kinase phosphorylation is a reversible reaction, and enzymes
called phosphatases catalyze the removal of phosphate groups from
substrate proteins and make it ready for the next cycle [4].
Kinase dysregulation, in majority of cases, is the result of
unchecked activity resulting in over-expression of proteins or
downstream genes, and such a state of increased activity has often
been positively correlated with many human diseases such as can-
cers, metabolic disorders, and infectious diseases. Several events
that modify kinases and leave them in elevated active states have
been identiﬁed [7]. A short list of these events include mutation [8],
up-regulation (gene ampliﬁcation) [9], simultaneous expression
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Table 1
List of kinase target receptors used in this study.
PDB ID Drug name EC # Gene UniProt Res. (Å)
1OPJ Imatinib 2.7.10.2 ABL P00520 1.75
3UE4 Bosutinib 2.7.10.2 ABL P00519 2.42
3GVU Imatinib 2.7.10.2 ABL P42684 2.05
3CS9 Nilotinib 2.7.10.2 ABL P00519 2.21
2GQG Dasatinib 2.7.10.2 ABL P00519 2.40
1T46 Imatinib 2.7.1.112 KIT P10721 1.60
3MIY Sunitinib 2.7.10.2 ITK Q08881 1.67
3K54 Dasatinib 2.7.10.2 BTK Q06187 1.94
1XBB Imatinib 2.7.1.112 Syk P43405 1.57
2PL0 Imatinib 2.7.10.2 LCK P06239 2.80
2ZVA Dasatinib 2.7.10.2 Lyn P25911 2.60
2OIQ Imatinib 2.7.10.2 cSRC P00523 2.07
3G5D Dasatinib 2.7.10.2 cSRC P00523 2.20
3GP0 Nilotinib 2.7.11.24 MAPK Q15759 1.90
3GCS Sorafenib 2.7.11.24 MAPK Q16539 2.10
1XKK Lapatinib 2.7.10.1 EGFR P00533 2.40
1M17 Erlotinib 2.7.10.1 EGFR P00533 2.60
2ITZ Geﬁtinib 2.7.10.1 EGFR P00533 2.80S. Ravichandran et al. / Journal of Molec
f multiple kinases [10], and increased expression of transporters
11].
Kinase dysregulation can be best understood by studying
hronic Myeloid Leukemia (CML). CML  is a unique disease caused
y unregulated kinase activity of a single malfunctioning gene, BCR-
BL [12], and is commonly invoked to understand the uncontrolled
ehavior of kinases. This disease is caused by the aberrant genetic
aterial called the Philadelphia chromosome, formed when a sec-
ion of DNA from chromosome-9 translocates to a region after
he BCR gene in chromosome-22. This creates a fusion gene, BCR-
BL, which expresses a protein product also called BCR-ABL [6,12].
nlike normal ABL, the fusion protein is constitutively active and
oes not require activation by external signals. Hence, BCR-ABL
emains active and participates in cell-cycle pathways, and strongly
nﬂuences cell-division and growth processes, leaving the affected
ell in a highly unstable state.
Other than aberrant genetic material formation, mutations
n and around the kinase active site can also inﬂuence kinase
ctivity [13]. For example, it had been observed that a small
raction of Philadelphia-positive (ph+) patients who  are under-
oing Imatinib therapy can relapse and offer resistance to the
herapy. This resistance has been attributed to the mutations in
he active site that reduces the drug’s ability to bind and inhibit
ctivity. Other forms of resistance to treatment have also been
ocumented. Notably, tumor cells tip the balance of regulating
hosphorylation–dephosphorylation in their favor by speciﬁcally
own-regulating the phosphatase to indirectly overcome receptor
nhibition [7].
Malfunction arising from a single gene such as BCR-ABL, can in
urn affect other down-stream pathway genes to create non-local
ffects. Since most cancers are associated with dysregulation of
ultiple genes involved in different pathways, the effect of mal-
unction can spread more rapidly than the single gene disease
o even affect far-away expressed gene products. Constitutional
ogue kinase activity or malfunction due to mutations can be con-
rolled by using either small molecule inhibitor drugs or humanized
ntibodies. The later approach of using a humanized antibody,
rastuzumab, to target ERBB2 receptors for treating breast cancer
as shown some potential, but the beneﬁt is not universal [14].
In cancer treatment, the idea of targeting multiple receptors
sing one or more drugs is not new [3,7,11,15,16]. Imatinib,
 drug known for inhibiting BCR-ABL, has also been identiﬁed
o inhibit platelet-derived growth factor (PDGF), stem-cell fac-
or (SCF) and c-KIT receptors. Imatinib (marketed as Gleevec
http://www.gleevec.com]) is currently being prescribed as a pri-
ary drug for treating both CML  [12] and GIST [11]. The justiﬁcation
or inhibiting multiple, but related, genes involved in disease
roliferation has been clearly illustrated [7] using the tyrosine
inase inhibitor PP121. PP121 was shown to inhibit PI3K and its
ownstream gene mTOR simultaneously, thus providing additional
eneﬁt of blocking both the negative feed loop initiator (mTOR) and
he oncogene, PI3K.
Using experimental and modeling data, a class deﬁnition for the
nhibitors (Type I/II) based on their chemistry and ability to trap
he kinases in an active or inactive conformation [17–22] has been
roposed. It is not clear whether the inhibitors force the kinases
oward a particular conformation or the receptors inﬂuence the
rug molecules to take a speciﬁc binding pose. Recent studies
17,19,21,23] have identiﬁed several key issues in kinase inhibi-
ion. Of signiﬁcance is the work by Davis et al. [18,19]; the most
laborate study known to date. These authors used 72 inhibitors
o create a selectivity proﬁle for more than 80% of the known
18 kinases. The important points arising from this study [19] are
hat the inhibitor Type (I/II) does not guarantee selectivity and,
ost importantly [24], the structural features that are presented
y the receptor during the binding often controls selectivity and3BBT Lapatinib 2.7.10.1 ERBB4 Q15303 2.80
1UWH Sorafenib 2.7.11.1 B-RAF P15056 2.95
therefore the choice of the best inhibitor. These ﬁndings will most
likely have a profound impact on basic research and future kinase
drug development.
To test these ﬁndings, receptor structure focused self- and cross-
docking simulations were performed using the experimentally
available small molecule kinase drug-bound PDB structures (19
in total) to analyze the respective binding modes and their corre-
sponding estimated afﬁnities. Our results qualitatively agree with
the known kinase inhibition proﬁles and that of Davis et al. [18,19].
Based on our data set, we  ﬁnd that receptor features dictate ligand
inhibition and Type II ligands in general are competitive for DFG-out
conformation. On the other hand, Type I ligands show less selectiv-
ity. Lapatinib appears to behave like a Type II molecule based on its
strong afﬁnity for inactive receptor folds but based on its atypical
receptor conformation (DFG-out and c-alpha helix conformation)
requirements [19], we have decided to place Lapatinib along with
Type-II ligands but without a Type classiﬁcation. Additional simu-
lations carried out on the wild-type and mutated protein system,
ABL, conﬁrm that the receptor structural features can qualitatively
capture the change in binding afﬁnities [13], and might be useful
for identifying potent family-speciﬁc inhibitors. The inﬂuence of
mutations on the binding afﬁnity was further analyzed using EGFR
and B-Raf kinase systems and the docking results show the change
in the binding afﬁnity and mean binding energy indicative of the
negative effect of selected mutations on binding. Finally, using the
common pathway information from our gene set, we  explore
the possibility of single drug or drug combinations that might be
useful for advanced stage cancers.
2. Materials and methods
2.1. Kinase systems
Protein kinase structures co-crystallized with drug molecules
were downloaded from RCSB-PDB (http://www.rcsb.org/pdb/) and
used for docking simulations. Kinase families studied in this work
include ABL, KIT, ITK, BTK, SYK, LCK, LYN, MAP, EGFR, erbB4, and
BRAF kinases (see Table 1). The small molecules examined in this
study are Dasatinib, Erlotinib, Sunitinib, Geﬁtinib, Bosutinib, Lapa-
tinib, Sorafenib, Nilotinib, and Imatinib (see Fig. 1). Note that these
are marketed small molecule drugs currently being used for the
treatment of different types of cancers and tumors. Each kinase
family was  searched in RCSB-PDB database for the availability of
3D structures that have been co-crystallized with drug molecules
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cig. 1. Chemical drawings of drug molecules studied in this work: chronic myelogen
HES);  non-small cell lung carcinoma (NSCLC); breast cancer (BC); lung cancer (LC
ancreatic neuroendocrine tumor (pNET); KIT positive (KIT+); Philadelphia chromo
rom our list; the best structure with high quality from the list was
ventually picked for docking simulations (see Table 1).
.1.1. Receptor structural information
The kinase receptor families (shown in bold face) used in this
tudy along with their RCSB PDB IDs (shown in parentheses) are:
BL1/2 (3UE4, 1OPJ, 3UE4, 3GVU, 3CS9) [25–28], C-KIT (1T46) [29],
TK (3MIY) [30], BTK (3k54) [31], SYK (1XBB) [32], LCK (2PL0) [33],
YN (2ZVA) [34], SRC (3G5D, 2OIQ) [35,36], EGFR (1M17, 1XKK,
ITZ) [37–39], ERBB4 (3BBT) [40], MAP  (3GP0, 3GCS) and B-RAF
1UWH) [41] (Table 1).
.2. Receptor preparation
The 3D coordinates for the kinase-inhibitor complexes were
ownloaded from RCSB (http://www.rcsb.org/pdb/). Molprobity
http://molprobity.biochem.duke.edu/) was used for analyzing
he PDB structures, adding hydrogens, and applying residue
ASN/GLU/HIS) ﬂips wherever applicable. The output from
olprobity was further analyzed using the SwissPdb Viewer
http://www.expasy.org/spdbv/) and Discovery Studio [ver. 3.5,
ccelrys Inc., San Diego, CA]. The protein structures were kept rigid
xcept during the ﬂexible in silico mutation experiments (see Sec-
ion 2.5), where only the mutated residue was allowed to rotate.
utoDockTools (ADT, version 1.5.6 rc3), a graphical-user-interface
or AutoDock, was used to prepare the molecules in AutoDock suit-
ble formats (pdbqt). Gasteiger-PEOE partial charges for molecules
ere added using ADT. AutoDock input parameter ﬁles for grid and
ocking (GPF, DPF; provided in the Supplemental Pages) were also
repared using ADT. Note that we did not make any attempt to
uild any missing receptor residue segments that are either away
rom the binding pocket or not involved in the binding..3. Ligand preparation
Ligand structures (Fig. 1) were downloaded from the NCBI Pub-
hem database (http://pubchem.ncbi.nlm.nih.gov/) and read intoukemia (CML); gastrointestinal stromal tumor (GIST); hypereosinophilic syndrome
al cell carcinoma (RCC); pancreatic cancer (PC); hepatocellular carcinoma (HCC);
 positive (Ph+). Drug release date is shown after their generic name.
Discovery Studio (Accelrys Inc., San Diego, CA) for further modiﬁ-
cation and analysis.
2.4. Docking Simulations
AutoDock [42–45] is an automated docking [46] method for
identifying the binding modes of ligands with biomolecule recep-
tors. AutoDock Vina [47] is the latest software from the AutoDock
family, but uses a different approach for identifying the bind-
ing modes and is also signiﬁcantly faster than AutoDock. In the
present study, AutoDock (ver 4.2.3; [45]) and Vina (ver 1.1.2) were
used for modeling the binding modes and/or estimating inhibi-
tion constants [48] because they both perform unbiased docking
and use atomistic details for describing the molecules [49,50]. A
brief summary of the AutoDock is provided in the Supplementary
Pages S1. Also, these two programs force ﬁelds had shown great
potential in reproducing crystal-bound conformations with high
accuracy. AutoDock (vers. 3 and up) uses a modiﬁed force ﬁeld [44]
that allows the user to also predict binding afﬁnities along with the
binding free energies.
2.4.1. AutoDock and AutoDockTools (ADT)
AutoDockTools [45] was  used for reading PDB ﬁles, adding H’s
and Gasteiger charges, and generating AutoDock input (pdbqt) ﬁles.
AutoGrid with a grid spacing of 0.375 A˚ (AutoDock: spacing param-
eter) was  used as a default spacing parameter in our simulations.
The grid box size was chosen to contain 100 × 100 × 100 grid points
(x, y and z direction) which was found to be large enough to cover
the kinase active site and important neighboring residues (see Sup-
plementary ﬁgure, Fig. S1). The center of the map  was  chosen for
each system using the co-crystallized ligand center of mass posi-
tion. ADT was used for generating the grid parameter ﬁle (GPF)
and the Docking Parameter File (DPF). The AutoDock Genetic Algo-
rithm runs were set as follows: ga run 200, population size is 300,
maximum number of energy evaluations is 2.5 × 107 (# of torsions
≤10) or 5.0 × 107 (# torsions >10). We  have invoked the AutoDock
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ost-processing step to carry out conformational clustering on the
nal docked conformations. Tolerance (rmstol) for the cluster anal-
sis was set to 2.0 A˚. Binding energies from the top-cluster were
veraged and reported as the mean-binding energy. A detailed list
f non-default AutoDock parameter options used in this study is
lso presented the Supplementary Section S1.
.4.2. Vina
AutoDock Vina’s scoring function and the method is detailed
lsewhere [47], here we review only the key points. Vina’s scoring
unction is based on X-score [51] and had been further adjusted
sing PDBbind [52–54]. Vina’s scoring function was developed to
ake advantage of both knowledge-based schemes and empirical
ethods. Unlike AutoDock, Vina does not use explicit hydrogen
toms or the partial charges for atoms in the simulations. Opti-
ization in Vina starts with a mutation of the ligand conformation
ollowed by a local optimization. The optimization algorithm used
s the Iterated Local Search Global Optimizer [55,56], and the accep-
ance or rejection follows the Metropolis criterion [13]. Sample of
ina input template conﬁg ﬁle is shown in Supplementary Section
2.
.4.3. Additional simulation details
The docking simulations were run on a Linux cluster (Intel
eon; nehalem) with the Ubuntu operating system (12.04.02).
inux C-shell scripts developed locally were used for PBS (portable
atch job) submission, post-processing and analysis. After the
imulations, the docked ligand conformations were extracted
nd compared with the crystal-bound conformation to esti-
ate whether the docking had identiﬁed the crystal-bound
onformation in the top ranking solutions. For this, root-mean-
quared-deviation (RMSD) between the docked solutions and
rystal-bound conformations were computed using locally devel-
ped FORTRAN software (f77 and f90; additional info in Supp.
ection S3). The post-analysis and ﬁgures were made using Dis-
overy Studio software (Accelrys Inc., San Diego, CA).
.5. Mutation in silico experiments
To analyze the role of receptor structural features of mutated
inase systems in inhibitor binding, we ﬁrst focused on the ABL
inases. The reason for choosing this system is because ABL kinases
re well-studied and the BCR-ABL related disease, CML, had been
lassiﬁed as a single-gene disorder. Hence, it is relatively easy to
tudy this system compared to other kinases. A 2009 study by
adaelli et al. [13] analyzed several key mutations that occur in
his kinase and their impact on the activity by monitoring the IC50
old changes. We  used the data set from this study as our main
eference for comparisons. Of all the mutations reported in the
bove mentioned work [13], we focused our modeling efforts on
wo highly resistant mutations, T315I and V299L. Mutated systems
ere prepared from the corresponding wild-type kinase struc-
ures: ABL1-Imatinib (PDB: 1OPJ), ABL1-Bosutinib (PDB: 3UE4),
BL1-Dasatinib (PDB: 2GQG) and ABL1-Nilotinib (PDB: 3CS9).
To study the impact of active site residue mutations on drug
inding and kinase activity, we examined the existing crystal struc-
ures of ABL kinase systems with T315I mutation. Three structures
PDB: 3QRI, 3QRJ, 3QRK) [57] have been reported with the T315I
utation. Upon structure comparisons of our T315I modeled struc-
ure with these three crystal structures, we found that with the
utated sequence still retained the WT  fold with a similar local
onformation around T315. For the V299L mutation, our searches of
he RCSB PDB database did not identify any relevant experimental
D structures. The two residues (V and L) involved in this sec-
nd mutation are both non-polar, side-chain ﬂexibilities are from
ow to moderate, and both could make minimal VDW interactionsraphics and Modelling 57 (2015) 36–48 39
with no possibility of forming H-bonds. So, we believe that ABL
should be able to accommodate the V299L point mutation and fold
similarly to the wild-type. Starting from the wild-type structures,
we introduced single point mutations in positions T315 and V299
separately to create two  mutant structures (ABL-T315I and ABL-
V299L). The mutated structures were further energy minimized
using Discovery Studio (ver. 3.5) to relieve any strain introduced
by the mutation. AutoDock has the capability of modeling a limited
number of ﬂexible residues. We  invoked this option to also carry
out both rigid and ﬂexible docking simulations for each mutated
system. Finally, we also extended our impact analysis to include
two additional kinase systems, EGFR (1M17:T766M; 1XKK:T790M)
and B-Raf (1UWH:E500G), to model the impact of selected muta-
tions that occur in the active sites of B-Raf and EGFR [58–60]. Note
that 1UWH:E500 occupies position E501 in the Uniprot sequence,
P15056. System preparation and the analysis for EGFR and B-Raf
and simulations were carried out as described above for the ABL
systems.
3. Results and discussion
Marketed kinase drug-bound complexes were collected from
the RCSB-PDB and the best structure based on resolution and R-
factors from each available family were chosen for docking (see
Fig. 1 and Table 1). A recent comprehensive experimental study
[19] was  able to show that the family-speciﬁc receptor structural
features play a key role in their inhibition, and further went on to
explore the possibility of developing unique inhibitors for different
kinase families. Using this study as a basis, we performed in silico
experiments using receptor-focused models to analyze the role of
receptor structural features on kinase inhibition. We  then explored
how inhibitors respond to the changes in the receptor features
in the active site to explain kinase inhibition and cross-reactivity
within, and across, different receptor families using pathway infor-
mation.
The structural transformation of kinases from inactive to active
forms involves many mobile regions, including a major movement
of an activation loop over several angstroms (see Fig. 2A). In spite
of several decades of work, many questions in the area of kinase
inhibition still remain unanswered. One straightforward approach
to model kinase inhibition is to employ dynamical methods, such
as Brownian dynamics [61] or molecular dynamics [62,63], and
follow the entire process. Simulations based on these or other novel
approaches [64] have been attempted before but the beneﬁts are
not universal across different kinase families. Moreover, most of
these approaches are computationally intensive and time could be
a factor in applying them for large datasets. A reasonable alter-
native is to model kinase inhibition by splitting the problem and
focusing separately on the most recurring active and inactive struc-
tures of the drug/inhibitor-bound experimental complexes and use
them as a reasonable starting point to understand inhibition. We
took this later approach to study kinase inhibition using structure-
focused models, followed by force-ﬁeld based docking simulations
and pathway-based analysis.
Kinase structures are often present in a dormant (inactive)
state prior to activation. Experimental structures representing both
active and inactive forms for most kinase families are readily avail-
able from RCSB Protein Data Bank (RCSB-PDB; www.rcsb.org). Since
kinase sequences from different families show overall similarity
with a common 3D bi-lobe fold, each family exploits the following
common sub-regions to create unique binding cavities for activ-
ity: (i) Catalytic loops, (ii) Nucleotide binding region, (iii) Hinge,
-helix, and (iv) DFG motifs. Experimental structures provide a
glimpse of the ﬂexible regions that play a key role during kinase
activation. The differences between active and inactive receptor
40 S. Ravichandran et al. / Journal of Molecular Graphics and Modelling 57 (2015) 36–48
Fig. 2. (A) Kinase 3D architecture differences between the inactive (IA; light green; shown on left) and active (A; cyan; shown on right) forms are highlighted using insulin
receptor kinase (IR3) as an example. Key functional domains are shown in different colors for visual clarity. The aligned structures were moved apart to show the differences.
(B)  Amino acid sequence of the insulin receptor (PDB: 1IR3; active form) is displayed along with the secondary structural information. Important structural domains (see A)
are  marked. The cyan background shows the range of the smaller N-terminal lobe (see A). Region between 8 and EF marks the Activation loop (shown using green box).
The  last six residues identiﬁed by a red separator correspond to the substrate peptide. (C) Zoomed-in view of the active site of the insulin receptor forms shown in A. The
proteins are shown in the aligned orientation and the color coding is similar to A. Note the difference in the orientation of residues, DF (part of the D1150F1151G motif), and
the  change in the position of activation loop (green) between the inactive (left) and the active (right) kinases. Phosphorylated PHE residues in the A-loop are shown in stick
mode.  The yellow color chain marks the substrate peptide. Ligand is shown in ball-and-stick and green balls mark the location of Mg ions.
S. Ravichandran et al. / Journal of Molecular G
Table  2
RMSD (Å) values for the AutoDock (ADT)/Vina predicted drug conformation to the
cocrystallized drug. The rank (R) of the modeling conformation from AutoDock and
Vina are also provided. AutoDock solutions are further clustered (Cluster size, C)
using a tolerance limit of 2.5 A˚.
Genes Kinase receptors (PDB ID) Drugs ADT(R,C) Vina (R)
ABL1 1OPJ Imatinib 2.11 (1,66) 11.61 (7)
ABL1 3UE4 Bosutinib 3.09 (1,7) 3.54 (3)
ABL2 3GVU Imatinib 1.90 (1,2) 5.05 (7)
ABL1 3CS9 Nilotinib 1.91 (1,126) 5.33 (1)
KIT  1T46 Imatinib 3.59 (1,5) 6.27 (6)
ITK  3MIY Sunitinib 4.24 (4,21) 4.67 (8)
BTK 3K54 Dasatinib 1.38 (2,18) 0.75 (4)
SYK 1XBB Imatinib 1.14 (2,14) 0.66 (2)
LCK 2PL0 Imatinib 1.60 (1,32) 3.80 (1)
LYN 2ZVA Dasatinib 1.36 (2,33) 0.28 (4)
SRC 2OIQ Imatinib 2.06 (1,87) 2.87 (1)
SRC 3G5D Dasatinib 0.82 (1,30) 0.89 (5)
MK11 3GP0 Nilotinib 2.87 (4,11) 3.39 (2)
MK14 3GCS Sorafenib 0.47 (1,176) 0.42 (1)
EGFR 1XKK Lapatinib 1.21 (1,10) 1.45 (3)
EGFR 1M17 Erlotinib 2.86 (2,63) 1.57 (2)
EGFR 2ITZ Geﬁtinib 2.51 (4,7) 3.32 (1)
ErbB4 3BBT Lapatinib 1.30 (1,6) 1.17 (1)
B-RAF 1UWH Sorafenib 0.62 (1,140) 0.67 (1)
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that is reﬂected in a high Spearman’s rank correlation ( = 0.685,
p-value = 0.035). For Dasatinib, the poor binding to SYK that wasinase conformations can be easily understood by comparing the
orresponding insulin kinase receptor structures (Fig. 2A–C). For
TP-competitive small molecule kinase inhibitor drugs, a grouping
ethod based on their abilities to recognize partner kinase struc-
ural conformations (active or inactive), using ABL kinase system
s a reference, has been proposed [17–22]. Using this formalism,
ype II ligands prefer to target inactive kinase conformations in
hich the DFG (one letter amino acid code) motif is present in a
DFG-out” conformation, and is not conducive to either ATP or sub-
trate binding. Due to differences in the held-in activation loop (see
ig. 2A–C) conformations, each inactive conformation can provide
 unique interaction site for inhibitors. These sites, in most cases,
ave been shown to be different for different kinase families, but
imilar among sub-families, and can be used to explain the varied
otencies for different inhibitor drugs. Type I ligands, on the other
and, do not depend on the unique DFG-out conformation for bind-
ng (Fig. 2C). Based on our structure-based docking results, it can be
een that the Type I ligands favor active kinase conformations. The
ctive kinase conformations are relatively more open than inactive
orms and on average are similar across different kinases.
Table 2 presents a comparison of AutoDock and Vina docking
esults against the experimentally co-crystallized conformations
sing Root Mean Squared Deviation (RMSD) measure (see Fig. 3).
ur docking results show that the overwhelming majority (17/19;
able 2) of the top-ranked docked solutions are found to be within
3 A˚ from their respective co-crystallized ligand conformations
see Fig. 3) with AutoDock, while only 10 of the 19 Vina con-
ormations show the ligand within 3 A˚ of the crystal structures.
ased on the RMSD measure, and the capability to estimate inhi-
ition constants, we focus on AutoDock computed results in this
aper; results of docking simulations using Vina are shown in the
upplementary Material (Table S1). Mean binding energies and
he estimated inhibition constants from AutoDock calculations are
hown in Tables 3 and 4, respectively. Each row in the tables quan-
itatively describes how different drug molecules respond to the
icro-environment a receptor presents. Each column provides a
rend of how a single drug molecule responds to the inﬂuence of
he shape of the active site and/or the changes in the key residues
ining the active site, and the results give an estimate of afﬁnity
nd cross-reactivity across different receptors. An extended form
f Table 3 is shown in Supplementary Table S2.raphics and Modelling 57 (2015) 36–48 41
Our simulations qualitatively capture the overall trends
observed by Davis et al. [19] and others [18]. Table 4 lists the
estimated inhibition constants [44,45] from docking simulations.
Binding energies and inhibition constants show that the Type
II or inactive receptor conformation favoring drugs are more
tightly bound compared to Type I or DFG-in, favoring ligands
(Tables 3 and 4). This can be clearly seen from the estimated inhibi-
tion constants between Type II (low nM)  predictions compared to a
high nM–M range for Type I ligands. For example, Erlotinib (type I)
shows weak binding to ABL1 (∼180 nM), which is indicative of less
compatibility to inactive fold when compared to Type II favoring
Imatinib (4.5 pM). In BRAF (PDB: 1UWH), the predicted inhibition
constants for Type II ligands show similar smaller values indicative
of strong binding (Lapatinib: 0.12, Nilotinib: 1.84, Sorafenib: 1.69)
than for the Type I drug molecules (Sunitinib: 273.30, Erlotinib:
489.68, Dasatinib: 17.34 nm,  etc.). Lapatinib has been assigned to
both Type I [65] and an undetermined Type [19] ligand. Our simu-
lation results show that Lapatinib exhibits preference for inactive
conformations and behaves more like a Type II when compared
to Type I molecules. On the other hand, it is also compatible with
open Type I folds (Tables 3 and 4). Using ABL as a reference, we  can
see that Lapatinib’s estimated inhibition constant (0.11 nm) is in
the low nM range and similar to Imatinib (4.5 pM). This trend for
Lapatinib is seen across the different receptors. For instance, with
EGFR (inactive conformation, PDB: 1XKK) the mean binding energy
is −12.43 kcal/mol compared to −8.57 kcal/mol for the active form
(PDB: 2ITZ) (Table 3).
The recently solved structure for the Bosutinib-bound ABL1
(PDB: 3UE4) uncovered an unique inactive kinase conformation
not previously observed in ABL kinases, and our results show that
its binding site structural features are incompatible with Type II
favoring drugs such as Imatinib and others (see Tables 3 and 4).
This is reﬂected in the mean binding energy that is estimated to
be around −7.95 kcal/mol for the ABL1-Bosutinib structure (PDB:
3UE4), compared to −14.79 kcal/mol in the ABL1-Imatinib kinase
structure (PDB: 1OPJ) (Table 3). Similar behavior is observed for
other Type II drug molecules reported in this study when inter-
acting with the PDB: 3UE4 (see Tables 3 and 4) binding pocket.
Examining the binding energy values for different receptors, one
can see that Bosutinib behaves like a Type I drug, even with a
receptor that exhibits an inactive fold, but more experimental evi-
dence is needed before it can be assigned to a speciﬁc type. Even
though the binding site features of ABL1 (PDB: 3UE4) are unique
in this case, it is not surprising since, as alluded earlier, the inac-
tive conformations can arise from different combinations of active
loop and c-helix conformations when compared to active forms,
and can be unique. Type II inhibitors from our set show higher
selectivity for the inactive active site than the active Type I site.
For example, Imatinib inhibits LCK (PDB: 2PL0, 0.26 nM)  but not
SYK (PDB: 1XBB, 318.76 nM), SRC (PDB: 3G5D; 149.21 nM), or LYN
(PDB: 2ZVA; 221.87 nM)  [33], and the selectivity of Lapatinib for the
inactive forms of EGFR are in the low nM range (Table 4). Estima-
tion of binding afﬁnity in modeling is a well-known challenge for
force-ﬁeld based methods and still needs improvement, especially
in predicting inhibition constants [48,66]. In spite of difﬁculties,
AutoDock qualitatively identiﬁes the correct trend. This is sup-
ported by the comparison with experiment shown in Supplemental
Table S6. In this table, the calculated inhibition constants are com-
pared to experimental dissociation constants [19]. Though these are
very different quantities, the qualitative trends are often in agree-
ment. A scatter plot of the calculated and experimental results for
Bosutinib shows a general monotonic trend (Supplemental Fig. S2),experimentally observed is also found computationally, as is the
relatively poor binding of Imatinib to LYN.
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To explore the mutual impact of the receptor-drug pair on each
ther during inhibition, we focused our attention on the well-
tudied drug Imatinib binding to different kinases. In our data set,
e have four different Imatinib bound kinase complexes (ABL,
IT, LCK, SRC) that were captured in the inactive conformation.
equence alignment for this set is displayed in Fig. 4A and the align-
ent was used as a guide to overlay the crystal structures (1OPJ,
T46, 2PL0 and 2OIQ) (Fig. 4A and B) using the PDB: 1T46 struc-
ure as a template. The co-crystallized ligands after alignment are
hown in Fig. 4B and C. One can see that the crystal bound ligands
fter alignment show that they all bind to their respective recep-
ors using very similar conformations, and the receptor features are
utlined in Fig. 4B and C. Comparison of the predicted inhibition
onstants from our set show that the ABL1 (PDB: 1OPJ, 0.0045 nM)
able 3
utoDock computed negative Mean-Binding Energies (MBE, kcal/mol). Receptor conform
one)  are also shown in parenthesis following their names.
Mode Gene PDB Dasatinib (I) Erlotinib (I) Sunitinib (I) Geﬁtin
IA ABL1 1OPJ 10.26 8.75 9.29 8.73 
IA  ABL1 3UE4 8.83 6.93 6.85 6.95 
IA  ABL2 3GVU 9.93 6.86 9.06 8.48 
IA  ABL1 3CS9 9.57 8.03 8.62 8.64 
IA  KIT 1T46 10.23 8.75 9.08 9.10 
A  ITK 3MIY 7.97 6.12 6.54 7.30 
A  BTK 3K54 9.07 6.83 7.31 7.59 
A  SYK 1XBB 7.39 6.18 6.30 6.54 
IA  LCK 2PL0 9.32 6.96 7.82 8.54 
A  LYN 2ZVA 8.89 6.82 6.04 7.17 
IA  SRC 2OIQ 9.00 7.22 8.13 8.36 
A  SRC 3G5D 9.83 7.12 6.38 8.04 
IA  MAPK11 3GP0 9.69 7.03 8.24 7.98 
IA  MAPK14 3GCS 8.69 7.58 8.11 7.98 
IA  EGFR 1XKK 9.75 8.06 7.88 7.96 
A  EGFR 1M17 8.35 6.56 7.01 7.32 
A  EGFR 2ITZ 8.57 6.57 6.60 7.00 
IA  ERBB4 3BBT 8.97 8.23 8.45 8.54 
IA  B-RAF 1UWH 9.81 7.90 8.63 9.26  stick) for key kinases studied in this work. (For interpretation of the references to
active site provides a very favorable environment for Imatinib and
it is therefore expected to bind stronger than to other kinases. For
instance, based on the predicted binding afﬁnity, the KIT binding
site is less conducive for Imatinib compared to ABL, PDB: 1T46
(2.56 nM). Even though the binding poses are very similar, the
predicted binding afﬁnities depend on the micro-environment as
shown in the structure-focused sequence alignment, Fig. 4A. For
example, the following non-conserved substitutions between 1T46
and 1OPJ could explain the differences in the binding afﬁnity:
Y672F, C673M, D677N, C788F, I808V and C809A. Note that the
last C to A change occurs a few residues ahead of the catalytically
important and well-known DFG motif.
We  used the BCR-ABL kinase system from our docking sim-
ulations to see whether we  could explain the IC50 fold changes
ational folds are indicated as Inactive (IA) or Active (A), and the drug types (I,II or
ib (I) Bosutinib Lapatinib Sorafenib (II) Nilotinib (II) Imatinib (II)
8.08 12.04 11.15 11.56 14.79
7.95 9.65 7.29 8.43 9.65
7.60 12.05 11.01 11.11 12.53
7.10 11.60 9.85 12.60 11.27
8.91 12.08 10.59 10.64 11.11
7.20 9.32 7.85 9.10 9.66
7.93 9.54 8.28 9.69 9.16
7.35 7.91 7.24 8.43 8.17
9.21 11.09 9.73 11.41 12.46
7.35 8.42 8.39 8.72 8.42
9.42 10.87 9.46 11.04 12.00
7.77 9.14 7.03 8.98 8.74
8.81 12.39 10.33 10.26 11.04
9.13 9.93 10.60 10.65 9.86
8.22 12.43 7.52 8.80 9.64
7.64 9.31 7.36 9.11 8.89
6.95 8.57 7.28 9.23 8.68
8.13 10.94 8.44 9.43 9.53
9.55 13.17 11.31 11.45 10.95
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Fig. 4. (A) Sequence alignment of Imatinib-bound inactive kinases, C-KIT: 1T46, ABL1: 1OPJ, SRC: 2OIQ, LCK: 2PL0 and ABL2: 3GVU (sequence identity: 22.3%; sequence
similarity: 41.3%). Sequence alignment was used as a guidance to align the corresponding structures and by choosing PDB ID 1T46 as the template. Residues in the 5 A˚ radius
sphere  surrounding the 1T46 co-crystallized Imatinib are highlighted in yellow. Key residue changes that could explain the difference in imatinib binding are marked in red
boxes.  (B) A 5 A˚  region surrounding the cocrystallized imatinib (see A) is shown in a backbone representation. The partial protein backbone structures are colored blue to
red  to show the N-terminal to C-terminal direction. The DFG motif is shown in stick form in atom type color. The reference protein (1T46) is identiﬁed by green color. RMSD
value  for each protein with reference to the template structure (1T46) is also shown in Supplemental Table S3. (C) Imatinib molecules from the corresponding PDBs (see A
and  B) are shown in overlayed form. 1T46 ligand is shown in green. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web  version
of  this article.)
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Table 4
AutoDock estimated inhibition constants (ki; nM). The co-crystallized ligand for the receptor is marked in underlined font. Receptor conformational mode (inactive: IA;
active:  A) is identiﬁed in the Mode column. Potent inhibitor identiﬁed by ki for each receptor (shown in column) is shown in italic font. Types of drugs (I or II), if identiﬁed,
are  shown in parenthesis following their name.
Mode Gene PDB Dasatinib (I) Erlotinib (I) Sunitinib (I) Geﬁtinib (I) Bosutinib Lapatinib Sorafenib (II) Nilotinib (II) Imatinib (II)
IA ABL1 1OPJ 13.70 179.79 91.30 168.18 446.70 0.11 3.56 3.38 0.0045
IA ABL1 3UE4 64.72 2760.00 6590.00 1730.00 685.71 27.17 2510.00 363.72 67.04
IA  ABL2 3GVU 17.33 3300.00 143.45 255.36 965.63 0.31 4.19 3.70 0.27
IA ABL1 3CS9 47.79 665.92 297.12 124.98 1220.00 0.55 19.55 0.24 0.74
IA  KIT 1T46 27.15 75.13 104.01 60.46 295.47 0.95 8.87 5.90 2.56
A ITK 3MIY 1430.00 4620.00 8440.00 1360.00 2750.00 25.40 639.49 149.76 20.56
A  BTK 3K54 102.28 2540.00 1060.00 924.91 506.92 53.44 255.68 37.22 68.91
A  SYK 1XBB 1030.00 8870.00 10560.00 4210.00 1850.00 70.83 3510.00 400.48 318.76
IA LCK 2PL0 49.03 3120.00 954.04 253.12 175.93 3.62 37.02 3.06 0.26
A LYN 2ZVA 30.90 2680.00 10040.00 1460.00 1340.00 93.06 255.79 224.16 221.87
IA  SRC 2OIQ 34.85 1510.00 201.93 292.06 34.74 4.93 54.91 4.32 0.59
A SRC 3G5D 17.00 1580.00 3990.00 348.00 574.50 43.89 2400.00 87.54 149.21
IA  MAPK11 3GP0 55.90 1950.00 578.42 554.03 185.46 0.15 8.80 14.19 6.34
IA  MAPK14 3GCS 65.22 921.85 375.57 161.60 203.14 52.97 8.25 10.22 43.69
IA  EGFR 1XKK 48.33 741.11 888.34 608.52 583.94 0.14 1510.00 159.71 25.93
A  EGFR 1M17 221.88 5580.00 3080.00 1520.00 1080.00 26.99 2150.00 81.45 82.59
A  EGFR 2ITZ 149.14 5300.00 7380.00 4900.00 1890.00 189.85 2690.00 85.71 223.98
IA  ERBB4 3BBT 116.18 178.58 294.00 181.26
IA  B-RAF 1UWH 17.34 489.68 273.30 75.61
Table 5A
AutoDock estimated inhibition constants (nM) and their corresponding fold
increases obtained from docking simulations for the wild-type (WT) and mutated
ABL  systems.
System 1OPJ/Imatinib 3UE4/Bosutinib 2GQG/Dasatinib 3CS9/Nilotinib
WT 0.0045 685.71 1.52 0.2376
V299L 0.0147 2690.00 8.15 0.1613
T315I 0.1128 3590.00 103.24 1.8900
o
m
C
i
g
i
t
w
b
t
o
[
t
o
s
s
c
s
o
n
d
w
t
t
T
b
b
k
a
b
aWT  1.00 1.00 1.00 1.00
V299L 3.26 3.92 5.36 0.68
T315I 24.95 5.24 67.92 7.95
bserved in mutated systems using a simple structure-focused
odel. The ABL system is chosen because (i) It is linked to diseases,
ML  and GIST, (ii) It is relatively easy to model the inhibition behav-
or because the diseases are attributed to the malfunction of a single
ene, (iii) It is a well-studied system with sufﬁcient experimental
nformation; and (iv) The ready availability of several experimen-
al structures. The results (Table 5A) show that using this approach,
e are able to qualitatively capture the changes due to mutation
y focusing on the receptor conformation. The key mutation, T315I,
hat causes the ABL systems to escape the inhibitory effects of not
nly Imatinib but also the second-generation drugs is well known
14]. Please note that position T315 is same as T334 in some of
he PDB systems described in Table 5A and Table S4, so, from now
n for clarity, we will only use T315 to identify this position. Our
imulations shows that Imatinib, Bosutinib, Dasatinib and Nilotinib
how fold changes of approximately 25, 5, 68, and 8 (see Table 5A)
ompared to their corresponding wild types. We  also followed a
econd mutation, V299L, which showed a relatively smaller effect
n the drug binding compared to the key T315I mutation. Please
ote that position V299 is same as V318 in some of the PDB systems
escribed in Table 5A and Table S4, so, from now on for clarity, we
ill only use V299 to identify this position. Our results follow the
rends observed for IC50 fold changes [13]. Flexible simulations for
hese systems follow similar order (see Suppl. Tables S4 and S5).
he idea of grouping ligands by Type I/II is deﬁnitely interesting,
ut when it comes to selectivity or identifying new compounds
ased on known Types is not informative [19,20]. Based on the
nown Types, one would expect ligands to be compatible only for
 speciﬁc family or sub-family receptors if the receptors are capa-
le of exhibiting speciﬁc active site arrangements during kinase
ctivity. Along these lines, similar binding afﬁnities of ligands to a 268.92 1.21 156.94 30.34 23.96
 63.81 0.12 1.69 1.84 4.50
receptor can provide information about their selectivity and recep-
tor 3D fold. For instance, the predicted inhibition constants of Type
II drugs such as Nilotinib, Sorafenib and a Type I drug Dasatinib are
similar and indicative of the fact that they are often used as second-
generation alternatives for Imatinib. When the receptor sequences
are modiﬁed by mutations, the binding behaviors of previously
known partner ligands start to deviate from their original asso-
ciated types. For example, as shown by our results for the newly
seen ABL receptor inactive fold (PDB: 3UE4), the known ABL Type
II drugs that target the inactive fold now become ineffective (1OPJ
vs. 3UE4 from Tables 3 and 4). Earlier studies have also shown that
different generations of Type II ligands are structurally different
from each other and even the newer generation Type II drugs also
contain a Type I scaffold [20].
This mutation analysis was  expanded by including two addi-
tional kinase systems, EGFR and B-Raf. The PDB structures used for
this analysis were EGFR: 1M17/1XKK and B-Raf: 1UWH. Experi-
mental studies on EGFR identify the gatekeeper residue mutation,
T790M, as a secondary mutation observed in NSCLC cell lines
which often lead to resistance for the binding of either Geﬁtinib
or Erlotinib [58–60]. The gatekeeper mutation and its structural
impact on the activity has also been addressed by Yun et al. [67].
They observed that T790M mutant binding pockets for both the
active and inactive conformations, have enough space to accommo-
date inhibitors, and, using their co-crystallized complexes, showed
that the inhibitor binding poses are very similar [67]. Our mutation
experiments using the inactive form of EGFR (1XKK) show simi-
lar or even better binding afﬁnities, but the active ones (1M17) are
negatively inﬂuenced by the mutation (Table 5B). Finally, the sim-
ulations for the B-Raf mutation E500G show the loss of glutamic
acid interactions when replaced with glycine. This mutation has
been observed in Cardio-facio-cutaneous (CFC) syndrome patients
[68] and, as our simulations show, could arise from the weakened
interactions from either loss of ﬂexibility, or H-bonds, or increase
in hydrophobicity (Table 5B).
The drug targets identiﬁed from docking simulations (see
Tables 3 and 4) were compared and found to show (Table 6) good
overall agreement with known experimental observations [18,19].
For Dasatinib, a Type I ligand, primary and secondary targets have
been identiﬁed by Davis et al. [18,19] as ABL1 and SRC. Based on our
simulations, estimated inhibition constants are 13.70 and 17.0 nM,
respectively. Using these estimates we  can assign ABL1 and SRC as
primary and secondary targets (see Table 6). Similar observations
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Fig. 5. (A) Pathway related information for the kinase genes studied in this work. DAVID web server (http://david.abcc.ncifcrf.gov/) was used for the calculation. Threshold
option  was set to count = 2, ease = 0.1. Please note that (S) denotes signaling pathway. (B) Pathways shown in A were clustered using kappa similarity with the following
options: Similarity threshold = 0.50, classiﬁcation: initial group membership = 3, ﬁnal group membership = 3, multiple linkage threshold = 0.50. Enrichment was  set to Ease
with  thresholds = 1.0. DAVID web server (http://david.abcc.ncifcrf.gov/) was  used for the calculation. Please note that (S) denotes signaling pathway.
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Table 5B
AutoDock estimated inhibition constants (nM) for the wild-type (WT) and mutated EGFR and B-Raf systems. Mutation numbering is based on the corresponding PDB structure.
Note  the 3-character (ex. STI) codes are the PDB assigned ligand IDs.
Gene System 1N1 AQ4 B49 IRE DB8 FMM  BAX NIL STI
PDB Dasatinib Erlotinib Sunitinib Geﬁtinib Bosutinib Lapatinib Sorafenib Nilotinib Imatinib
BRAF 1UWH WT 17.34 489.68 273.30 75.61 63.81 0.12 1.69 1.84 4.50
E500G 24.48 399.73 550.39 156.46 33.26 2.67 21.09 9.58 18.15
EGFR  1M17 WT 221.88 5580.00 3080.00 1520.00 1080.00 26.99 2150.00 81.45 82.59
T766M 5470.00 8370.00 10840.00 3100
1XKK  WT 48.33 741.11 888.34 608
T790M 15.69 188.58 2000.00 733
Table 6
Comparison of kinase drug targets from Davis et al. (Nature Biotech, V29, 1046,
2011) with docking simulations.
Drugs (type) Primary Secondary and others Docking
Dasatinib(I) ABL1 SRC ABL1, SRC
Erlotinib(I) EGFR KIT, erbB4, EGFR
Sunitinib(I) KIT VEGFR2 ABL1, KIT
Geﬁtinib(I) EGFR KIT, BRAF
Lapatinib ERBB2 EGFR ABL1, BRAF, EGFR
Sorafenib(II) VEGFR2 BRAF, FLT3 BRAF, ABL1
Bosutinib ABL1 SRC SRC, BRAF
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iNilotinib(II) ABL1 KIT ABL1, BRAF SRC, KIT
Imatinib(II) ABL1 KIT ABL1/2, KIT, LCK
or other systems had also been reported in other studies as well
19,69]. The approximations involved in structure-based modeling,
nfortunately, also lead to some discrepancies. For example, the
redicted binding afﬁnities for Lapatinib, a drug molecule that is
nown to mostly target inactive folds, agrees qualitatively but not
uantitatively with the experiments [19]. The differences could be
ue to the approximations involved in modeling solvents and the
ynamical effects. Since biological effects such as bioavailability are
ot inherently modeled, the binding ability for a ligand will be true
nly if the drug can successfully reach the active site. For example,
ioavailability could be the reason why for some systems (EGFR-
eﬁtinib, PDB: 2ITZ), the co-crystallized ligand is not identiﬁed as
he potent binder. Our future efforts will focus to include pathway
nformation to address these issues.
Drug resistance arising from non-mutation mechanisms, as
bserved in EGFR systems, are also a major concern for both
atient treatment and drug discovery. A 2010 study by Knight
t al. [7] elegantly proposed a polypharmacology-based cautious
pproach on how to choose effective therapeutic targets that
ight lead to less toxic side-effects, but still could lead to com-
lete inhibition. In advanced stage cancers, targeting multiple
ut related pathways appears to be a reasonable and necessary
ption. In an attempt to identify the pathway represented by kinase
inase receptor set, we used the functional annotation tool DAVID
http://david.abcc.ncifcrf.gov) to carry out an enrichment analysis.
he list of common pathways for our gene set and the top clus-
ers based on functional annotation are shown in Fig. 5A and B
espectively. The top cluster (Fig. 5B) from our annotation results is
he Fc epsilon RI signaling pathway. This pathway involves sev-
ral signaling molecules and the participating mediators often
ontribute to inﬂammatory response events. This signaling path-
ay involves BTK, SYK, LYN and MAPK kinases from our set. As
ne can see from the KEGG pathway chart (KEGG: hsa04664;
ttp://www.genome.jp/dbget-bin/www bget?hsa04664) LYN is
resent upstream of BTK, SYK and MAPK. Our results indicate that
asatinib or Lapatinib can be used as a drug to effectively tar-
et all of these kinases. Over-expression of ABL kinases have been
bserved in several breast cancer cases and often contributes to
ver-active cell growth [70]. The most common pathway (Fig. 5A)
n our data set is the ErbB pathway. A KEGG pathway map  (KEGG:.00 7720.00 134590.00 2690.00 349400.00 143.00
.52 583.94 0.14 1510.00 159.71 25.93
.05 323.07 1.76 844.81 66.38 96.38
hsa04012) shows that ABL genes are present downstream of EGFR.
Experimental studies show that in breast cancer patients ABL activ-
ity seems to protect the activated EGFR from dephosphorylation
by phosphatase [71,72]. So instead of inhibiting EGFR alone, it
would be therapeutically rewarding to design a treatment that also
includes ABL. Recent experiment by Yuan-Hung Lo et al. [24] tested
this hypothesis and found evidence that a combined therapy that
uses the dual kinase inhibitor Tykerb (Lapatinib) along with Imat-
inib showed improved therapeutic beneﬁt and responsiveness for
breast cancer treatment than using only Lapatinib. Our simulation
(Table 4) results show that Lapatinib and Imatinib are compatible
with the active-sites of ABL and EGFR, and the results qualitatively
agree with the experimental observations. For example, our simu-
lations show that Imatinib and Lapatinib being the potent inhibitors
for ABL kinases (e.g. 3GVU: 0.27/0.31) and EGFR (1XKK: 25.93/0.14),
respectively (Table 4). The additive effect of these drugs is beyond
the scope of this study and needs experimental evaluation.
4. Conclusions
This study examined the interaction of nine commercially avail-
able kinase inhibitors with different kinases and selected mutants.
These results show that the overwhelming majority of the docking
experiments (90%, 17/19, RMSD <3 A˚, see Table 2) were able to cor-
rectly identify the experimentally observed binding mode within
the top 4 ranked conformations. The estimated inhibition constants
also qualitatively follow the experimentally observed trend, thus
highlighting the need for incorporating the characteristic confor-
mation of the receptor (active or inactive) as a key early step in
modeling kinase inhibition. One of the goals of this work is to see
whether insight into cross-reactivity can be gained. Our results
show that drug molecules that belong to Type II (e.g. Imatinib, see
Tables 3 and 4) are more selective of the receptor structural fea-
tures during binding when compared to Type I (e.g. Erlotinib, see
Tables 3 and 4) ligands. This appears to follow from the fact that
the active kinase conformations are more open and similar to each
other when compared to the inactive ones. On the other hand, inac-
tive active site functional group arrangements are different from
each other and contributes to the selectivity of the drugs that favor
these conformations [19]. To further explore the importance of the
effect of kinase conformations on the selectivity, two key muta-
tions, T315I and V299L, of the ABL gene (Table 5A) were examined.
The docking results were able to qualitatively capture the effects
of these key mutations for the most common ﬁrst and second gen-
eration drugs used for treating CML  patients with these mutations.
Mutation effects were further examined by analyzing two  addi-
tional systems, EGFR and B-Raf. The results show (Table 5B) that
wild-type inhibitors lose key binding interactions upon receptor
mutation; the weakening effect is reﬂected in the increase of the
inhibition constants.
Kinase conformations retain clues on its selectivity for the
inhibitors; hence a speciﬁc drug can be an effective inhibitor for
two different receptors as long as these proteins can provide the
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ommon conformation (e.g. inactive or active form) with sim-
lar active site residues. Also, the ligand Types can be used to
nderstand cross-reactivity, but it is kinase family-speciﬁc and
here are exceptions.
It is well-known that modeling kinase inhibition is a challenge.
 recent study using a large data set was able to identify key
ssues such as structural features and the roles of ligand Types in
inase inhibition [19]. Using these observations as basis, a receptor-
ocused modeling and docking approach can correctly predict the
inase proﬁle across a wide-range of kinase families. Ligand Types
re often characterized based on their abilities to target the recep-
or ATP binding pocket when the activation loop is either present
n the compact inactive or active open conformations. When the
igand contains an extra functional group(s), they fail to behave like
he parent ligands [20]; hence the focus should be on the receptor.
ven though there are experimental methods that are success-
ul in identifying the common binding mode of kinase inhibitors,
he concept of dynamic equilibrium during kinase activation can-
ot be ignored [20]. As elegantly pointed out by Chene [66] and
thers, the inﬂuence of pharmacokinetics [20] and slow off-rates
ontinue to daunt [38] the prediction efforts. Speciﬁcally, ligands
hat target active kinase forms prefer to bind near the edge of the
ctive site region and have portions of their molecule exposed to
he solvent. In such cases, for example the simulation systems like
ene/PDB ID (BTK/3k54, SYK/1XBB, LYN/2ZVA, EGFR/2ITZ), sol-
ation effects may  dominate the binding and hence an accurate
escription of these effects have to be included in the modeling
o properly estimate binding afﬁnities. As noted by Kitchen et al.
46], in such cases scoring and further ranking the docking solutions
ecomes difﬁcult. In spite of these issues, by focusing on the struc-
ural features, these docking simulations were able to correctly
redict binding modes and the trends in kinase inhibition. Future
fforts should focus on three fronts: (a) Developing a receptor-
ased pharmacophore with spatial constraints to include receptor
esidues as exclusion areas to improve the estimation of binding
fﬁnities; (b) Inclusion of the impact of conformational changes
f key residues in the active site on the estimation of inhibition
onstant; and (c) A combined approach of using analytic learning
ethods along with docking simulations to model cross-reactivity
nd toxicity [73].
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